Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc., a clinical-stage oncology biotech using artificial intelligence (AI) and genomics to innovate the rescue, revitalization, and development of precision cancer therapeutics. Lantern is focused on improving patient outcomes by using its proprietary AI platform – Response Algorithm for Drug Repositioning & Rescue (RADR®) – to rescue, revitalize and develop abandoned or failed cancer drugs, and to accelerate their development through precision trials that help identify patient groups more likely to respond to its pipeline of targeted cancer therapies.